Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

ClinicalTrials.gov ID: NCT03691649

Public ClinicalTrials.gov record NCT03691649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current topical IOP-lowering medication(s), if any. After completing the required washout period, subjects will return for Visit 2 (Baseline, Day 1). Subjects who meet all eligibility criteria at baseline will be randomized to receive double-masked treatment for 3 months. Adult subjects will receive open-label DE-117 Ophthalmic Solution for an additional 9 months. Approximately 400 adult subjects and up to 30 pediatric subjects with glaucoma or OHT who meet all eligibility criteria will be randomized in a 1:1 ratio to receive either: * DE-117 Ophthalmic Solution once daily and Vehicle once daily, or * Timolol Maleate Ophthalmic Solution 0.5% twice daily. The study will evaluate the efficacy and safety of DE-117 Ophthalmic Solution compared with Timolol Maleate Ophthalmic Solution 0.5% in subjects with glaucoma or OHT through Month 3 and will provide additional safety data through Month 12 for subjects receiving DE-117.

Study identification

NCT ID
NCT03691649
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Santen Inc.
Industry
Enrollment
426 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Months and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 13, 2018
Primary completion
Dec 5, 2019
Completion
Sep 2, 2020
Last update posted
Aug 29, 2023

2018 – 2020

United States locations

U.S. sites
47
U.S. states
23
U.S. cities
43
Facility City State ZIP Site status
Arizona Glaucoma Specialists Phoenix Arizona 85050
DocTrials Walman Eye Center Sun City Arizona 85351-3019
Havana Research Institute Burbank California 91506
Macy Eye Center Los Angeles California 90048-6149
North Valley Eye Medical Group Mission Hills California 91345
North Bay Eye Associates, Inc Petaluma California 94954
Martel Eye Medical Group Rancho Cordova California 95670
Samsum Clinic (DocTrials) Santa Barbara California 93110
MCB Clinical Research Centers LLC Colorado Springs Colorado 80909
Hernando Eye Institute Brooksville Florida 34613-6065
Eye Associates of Fort Myers Fort Myers Florida 33901-9311
Bowden Eye & Associates Jacksonville Florida 32256
Shettle Eye Research Largo Florida 33773
Dixophthal PC Dba. Dixon Eye Care Albany Georgia 31701-2363
Coastal Research Associates Alpharetta Georgia 30076
Clayton Eye Clinical Research, LLC Morrow Georgia 30260
Indiana University Bloomington Indiana 47405
Heart of America Eye Care, P.A. Shawnee Mission Kansas 662204
Clinical Eye Research of Boston, LLC Winchester Massachusetts 01890
Tauber Eye Center Kansas City Missouri 64111
Nevada Eye Care Professionals Las Vegas Nevada 89119
Wellish Vision Institute Las Vegas Nevada 89119
AdvanceMed Clinical Research-Las Vegas Las Vegas Nevada 89123-2810
Northern New Jersey Eye Institute South Orange New Jersey 07079-1855
NY Eye & ear Infirmary of Mt Sinai (NYEE) New York New York 10003
South Shore Eye Care, LLP Wantagh New York 11793
Asheville Eye Associates Asheville North Carolina 28803-2493
Charlotte Eye Ear Nose & Throat Associates, PA Charlotte North Carolina 28210
Cornerstone Eye Care High Point North Carolina 27262
Apex Eye Clinical Research, LLC Cincinnati Ohio 45242
Ophthalmic Surgeons & Consultants of Ohio, Inc. Columbus Ohio 43215
Office of Mark J. Weiss MD Tulsa Oklahoma 74104-5300
Scott & Christie and Associates PC Cranberry Township Pennsylvania 16066
Glaucoma Consultants and Center for Eye Research PA Mt. Pleasant South Carolina 29464-8298
Black Hills Regional Eye Institute, LLP Rapid City South Dakota 57701
University Eye Specialists Maryville Tennessee 37803
Total Eye Care PA Memphis Tennessee 38119-5770
Keystone Research Ltd. Texan Eye PA Austin Texas 78731-4203
The Cataract and Glaucoma Center El Paso Texas 79902
Ophthalmology Associates Fort Worth Texas 76102
Shah Research LLC dba Discovery Clinical Trials Mission Texas 78572-2425
San Antonio Eye Center San Antonio Texas 78215-1936
R and R Eye Research LLC San Antonio Texas 78229
Delay Winter Eye Consultants LLC San Antonio Texas 78230-5141
Stacy R. Smith M.D. P.C. Salt Lake City Utah 84117-5209
Emerson Clinical Research Institute Falls Church Virginia 22046
Specialty Eye Care Centre Bellevue Washington 98004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03691649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 29, 2023 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03691649 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →